

Errata

Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. *Blood*. 2014;124(2):188-195.

On page 192 in the 10 July 2014 issue, there are errors in Table 3. In the “Dose” column, the units for the doses of all vasopressors listed except dopamine should read “ $\mu\text{g}/\text{min}$ ” rather than “ $\mu\text{g}/\text{kg}/\text{min}$.” The corrected table is shown below. The error has been corrected in the online version, which now differs from the print version.

Table 3. High-dose vasopressors (all doses are required for ≥ 3 hours)

Pressor	Dose
Norepinephrine monotherapy	$\geq 20 \mu\text{g}/\text{min}$
Dopamine monotherapy	$\geq 10 \mu\text{g}/\text{kg}/\text{min}$
Phenylephrine monotherapy	$\geq 200 \mu\text{g}/\text{min}$
Epinephrine monotherapy	$\geq 10 \mu\text{g}/\text{min}$
If on vasopressin	Vasopressin + norepinephrine equivalent of $\geq 10 \mu\text{g}/\text{min}^*$
If on combination vasopressors (not vasopressin)	Norepinephrine equivalent of $\geq 20 \mu\text{g}/\text{min}^*$

*VASST Trial vasopressor equivalent equation: norepinephrine equivalent dose = [norepinephrine ($\mu\text{g}/\text{min}$)] + [dopamine ($\mu\text{g}/\text{kg}/\text{min}$) $\div 2$] + [epinephrine ($\mu\text{g}/\text{min}$)] + [phenylephrine ($\mu\text{g}/\text{min}$) $\div 10$].

DOI 10.1182/blood-2015-07-656918

Cervantes F. How I treat myelofibrosis. *Blood*. 2014;124(17):2635-2642.

On page 2638 in the 23 October 2014 issue, there is an error in Table 1. In the “Phase” column, the entry for fedratinib (SAR302503), which reads “2 (withdrawn),” should read “3 (withdrawn).” The corrected table is shown below. The error has been corrected in the online version, which now differs from the print version.

Table 1. JAK inhibitors tested in clinical trials in MF

Agent	Other targets	Phase
Ruxolitinib	JAK1	3 (approved)
Fedratinib (SAR302503)	FLT3, RET	3 (withdrawn)
Pacritinib (SB1518)	FLT3	3
Momelotinib (CYT387)	JAK1, JNK1, TYK2, CDK2, RICJ2	3
Lestaurtinib (CEP-701)	FLT3, TRKA	2 (withdrawn)
AZD1480	JAK1, JAK3, FLT4, FGFR1, TRKA	2
Gandotinib (LY2784544)	—	1 (withdrawn)
XL019	—	1 (withdrawn)
NS-018	SRC, FLT3, ABL	1/2
BMS-911543	—	1/2 (withdrawn)

DOI 10.1182/blood-2015-07-656892

© 2015 by The American Society of Hematology